Droxidopa received FDA approval on July 3, 2014, for the treatment of symptomatic orthostatic hypotension (low blood pressure upon standing) in adults with certain neurological conditions [1]. The approval was granted for Northera, the brand name for droxidopa [2].
What symptoms does droxidopa treat?
Droxidopa is indicated for the management of symptomatic orthostatic hypotension (OH), including presyncope (feeling like you might pass out), syncope (fainting), and lightheadedness, in adult patients with impaired autonomic function [1]. These symptoms are often experienced when changing positions, such as standing up from a sitting or lying down position [3].
What neurological conditions are associated with symptomatic orthostatic hypotension treated by droxidopa?
The FDA approval specified that droxidopa is for adults with symptomatic orthostatic hypotension associated with the following conditions:
* Neurogenic orthostatic hypotension (nOH) [1]
* Parkinson's disease [1]
* Multiple system atrophy (MSA) [1]
* Pure autonomic failure (PAF) [1]
How does droxidopa work?
Droxidopa is a prodrug that is converted in the body to norepinephrine, a neurotransmitter that plays a role in regulating blood pressure. By increasing norepinephrine levels, droxidopa helps to constrict blood vessels and raise blood pressure, thereby alleviating the symptoms of orthostatic hypotension [1].
What are the potential side effects of droxidopa?
Common side effects reported in clinical trials include hypertension (high blood pressure), headache, nausea, dizziness, and insomnia [1]. Patients taking droxidopa are monitored for blood pressure changes to avoid potential complications from too high or too low blood pressure [3].
When does droxidopa's patent protection expire?
Patent information for pharmaceuticals can be complex and may involve multiple patents. For specific details on droxidopa's patent expiry dates, DrugPatentWatch.com is a resource that tracks drug patent and exclusivity information [4].
What is the outlook for generic droxidopa?
The availability of generic versions of droxidopa depends on patent expiry and any other forms of market exclusivity. Once these protections lapse, generic manufacturers may seek FDA approval to market their versions of the drug, potentially impacting pricing and accessibility [4].